Optimum control of blood glucose for prevention and treatment of ischemic and hemorrhagic stroke

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 3, 2009, Pages 201-211

  Guyomard, Veronique ^b   Myint, Phyo Kyaw ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHLORAMPHENICOL; CIMETIDINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN DERIVATIVE; LIPID; MEGLITINIDE; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PROBENECID; ROSIGLITAZONE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VITAMIN B GROUP; WARFARIN;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; APLASTIC ANEMIA; BLOOD DISEASE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ERYTHEMA; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FATIGUE; FRACTURE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; INCREASED APPETITE; INJECTION SITE REACTION; LACTIC ACIDOSIS; LEUKOPENIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER FAILURE; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; LUNG EDEMA; MORBIDITY; MORNING DOSAGE; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSTRUCTIVE JAUNDICE; PANCYTOPENIA; PARESTHESIA; PROGNOSIS; PRURITUS; RETINA MACULA EDEMA; REVIEW; RISK MANAGEMENT; SECONDARY PREVENTION; SIDE EFFECT; SINGLE DRUG DOSE; TASTE DISORDER; THROMBOCYTOPENIA; URTICARIA; VOMITING; WEIGHT GAIN;

EID: 65549147262     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0021-9     Document Type: Review

References (36)

1. National Diabetes Information Clearinghouse (NDIC): National diabetes statistics, 2007. Available at http://www.diabetes.niddk.nih.gov/DM/PUBS/ statistics. Accessed March 2009.
2. Howard G, Bergman R, Wagenknecht LE, et al.; Insulin Resistance Atherosclerosis Study (IRAS) Investigators: Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model". Ann Epidemiol 1998, 8:358-369.
3. Saydah S, Miret M, Sung J, et al.: Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001, 24:1397-1402.
4. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 25:1157-1164.
5. Boden-Albala B, Cammack S, Chong J, et al.: Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events. Diabetes Care 2008, 31:1132-1137.
6. The ACCORD Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
7. Idris I: Safety of very tight glucose control in type 2 diabetes in question diabetes, obesity and metabolism. Diabetes Obes Metab 2008, 10:438-440.
8. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
9. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
10. Goldstein LB, Adams R, Becker K, et al.: Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001, 32:280-299.
11. UK Prospective Diabetes Study Group: Intensive blood-glucose with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
12. National Heart, Lung, and Blood Institute: For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease [press release]. Available at http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551. Accessed March 2009.
13. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
14. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
15. Riddle M, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators: The trRat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086.
16. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730.
17. Gilmore RM, Stead LG: The role of hyperglycemia in acute ischemic stroke. Neurocrit Care 2006, 5:153-158.
18. Furie K, Inzucchi SE: Diabetes mellitus, insulin resistance, hyperglycemia, and stroke. Curr Neurol Neurosci Rep 2008, 8:12-19.
19. Matthews DR, Holman R: UKPDS 30 year data-are there legacy effects of improved glucose and blood pressure control? Presented at the 44th Annual Meeting of the European Association for the Study of Diabetes. Rome, Italy; September 7-11, 2008.
20. Levetan CS: Effect of hyperglycemia on stroke outcomes. Endocr Pract 2004, 10(Suppl 2):34-39.
21. Myint PK, Sinha S, Wareham NJ, et al.: Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: A threshold relationship? Stroke 2007, 38:271-275.
22. Mellbin LG, Malmberg K, Norhammar A, et al.: DIGAMI 2 Investigators: The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: A report from the DIGAMI 2 trial. Eur Heart J 2008, 29:166-176.
23. Lapcevic M, Vukovic M, Dimitrijevic I, et al.: The effect of medicamentous and non-medicamentous therapy on lowering risk factors for cardiovascular and cerebrovascular episodes in an interventional study [in Serbian]. Srp Arh Celok Lek 2007, 135:554-561.
24. Kunte H, Schmidt S, Eliasziw M, et al.: Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007, 38:2526-2530.
25. Mazzone T: Prevention of macrovascular disease in patients with diabetes mellitus: Opportunities for intervention. Am J Med 2007, 120(Suppl 2):S26-S32.
26. Sobel BE: Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 2007, 120(Suppl 2):S3-S11.
27. Ivey FM, Ryan AS, Hafer-Macko CE, et al.: Treadmill aerobic training improves glucose tolerance and indices of insulin sensitivity in disabled stroke survivors: A preliminary report. Stroke 2007, 38:2752-2758.
28. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group: Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008, 359:1464-1476.
29. Ligaray KP, Isley WL: Diabetes mellitus, type 2-endocrinology. Emedicine website. http://emedicine.medscape.com. Accessed August 6, 2008.
30. Votey SR, Peters AL: Diabetes mellitus, type 2 - a review - emergency medicine. Emedicine website. http://emedicine.medscape.com. Accessed July 9, 2008.
31. Lamb WH: Diabetes mellitus, type 1G- pediatrics: general medicine. Emedicine website. http://emedicine.medscape.com. Accessed October 19, 2007.
32. British National Formulary: BNF 57. Available at http://www.bnf.org/bnf/ index.htm. Accessed March 2009.
33. National Institute for Health and Clinical Excellence: Type 2 diabetes. The management of type 2 diabetes. NICE clinical guideline 66. Available at http://www.nice.org.uk/nicemedia/pdf/CG66NICEGuideline.pdf. Accessed March 2009.
34. Munro N, Feher MD: Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetes. Br J Gen Pract Vol. 58:531-533.
35. JianN WJ: Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 2008, 373:341-344.
36. Nayagam VM, Wang X, Tan YC, et al.: SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006, 11:959-967.